Novo Nordisk | NVO - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
ANI Pharmaceuticals USD 73.66M 9.14M 2026-03
Aurora Cannabis CAD 40.62M 1.17M 2025-12
Bausch Health Companies USD 813M 12M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Canopy Growth CAD 28.9M 636K 2025-12
Corcept Therapeutics USD 128.04M 13.3M 2026-03
Drreddys Laboratories INR 26.92B 3.74B 2025-12
Eli Lilly USD 2.93B 198M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Merck USD 2.67B 180M 2026-03
Nektar Therapeutics USD 10.17M 10.17M 2025-12
Novartis USD 3.14B 296M 2026-03
Novo Nordisk DKK 13.22B 4.22B 2026-03
Novo Nordisk DKK 2.86B 13.25B 2025-06
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 267.3M 11.4M 2026-03
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 29.67M 1.64M 2025-12
Sanofi EUR 2.33B 419M 2026-03
Supernus Pharmaceuticals USD 118.23M 4.16M 2026-03
Zoetis USD 588M 31M 2026-03